Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$880.87 USD

880.87
344,687

-4.68 (-0.53%)

Updated Oct 4, 2024 10:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, ConocoPhillips & PNC Financial

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), ConocoPhillips (COP), and The PNC Financial Services Group, Inc. (PNC).

ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review

by Zacks Equity Research

ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.

Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata

by Zacks Equity Research

The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.

Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug

by Zacks Equity Research

Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo

by Zacks Equity Research

Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide

by Kinjel Shah

FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).

Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FVD

Kinjel Shah headshot

4 Large Drug Stocks to Watch as the Industry Recovers

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.

AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies

by Zacks Equity Research

AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.

Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod

by Zacks Equity Research

Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update

by Kinjel Shah

Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.

    Lilly's (LLY) Olumiant Gets Full Approval From FDA for COVID

    by Zacks Equity Research

    The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.

    Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

    by Zacks Equity Research

    Sector ETF report for PJP

    ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates

    by Zacks Equity Research

    ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.

    Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline

    by Zacks Equity Research

    Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.

    Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track

    by Zacks Equity Research

    Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.

    Should Invesco Dynamic Large Cap Growth ETF (PWB) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for PWB

    United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up

    by Zacks Equity Research

    United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

    Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates

    by Zacks Equity Research

    Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.

    Kinjel Shah headshot

    Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE

    by Kinjel Shah

    Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.

    Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for FVD

    Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises

    by Zacks Equity Research

    Eli Lilly (LLY) beats first-quarter estimates for both earnings and sales and ups its sales outlook for 2022. The stock rises in pre-market trading.

    GDP Declined in First Quarter

    by Zacks Equity Research

    GDP Declined in First Quarter

    Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute

    by Zacks Equity Research

    Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.

    Mark Vickery headshot

    Q1 GDP Negative; Q1 Earnings Beats from CAT, LLY, MCD

    by Mark Vickery

    GDP reported the first negative quarter since Q2 2020, which was considered the "heart" of the pandemic.